STUDY POPULATION
CF patients (n=117) who have commenced inhaled aztreonam lysine therapy across 9 CF centres
STUDY DESIGN
Retrospective chart notes review 1 year pre and post treatment with CAYSTON® using SVMPharma’s Treatment Evaluator tool
STUDY OUTCOME
Significantly improved lung function and weight. Reduced hospitalisation and exacerbation rates



SVMPharma’s innovative RWE solutions
Chart note is a rich and valuable source of RWE data
SVMPharma’s Treatment Evaluator tool helps collect this data
Real-world data helps inform treatment pathways and standard of care
SVMPharma’s RWE helps track comparator outcomes and routine clinical practices
Real-world data collection backed by KOLs
SVMPharma ensures real-world data is clinically relevant by engaging with KOLs
Reference: B. Plant et al. A treatment evaluator tool to monitor the real-world effectiveness of inhaled aztreonam lysine in cystic fibrosis. Journal of Cystic Fibrosis 2017;16:695–701